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ROI γ 
parameter 
|D1EPID 
– 
D1plan| 
(%pt) 
|D50EPID 
– 
D50plan| 
(%pt) 
|D99EPID 
– 
D99plan| 
(%pt) 
|EUD(1)EPID 
/ 
EUD(1)plan| 
(%) 
|EUD(7)EPID 
/ 
EUD(7)plan| 
(%) 
PTV pass rate -0.68 -0.92 0.25 -0.92 -0.91 
PTV γ1% 0.95 0.84 -0.04 0.87 0.89 
PTV mean-γ 0.85 0.97 -0.15 0.98 0.98 
30%-
PTV 
pass rate 
-0.79 -0.85 -0.41 -0.83 -0.80 
30%-
PTV 
γ1% 
0.68 0.85 0.76 0.83 0.75 
30%-
PTV 
mean-γ 
0.95 0.98 0.32 0.99 0.98 
50% pass rate -0.79 -0.73 -0.50 -0.74 -0.76 
50% γ1% 0.99 0.99 0.84 0.99 0.99 
50% mean-γ 0.96 0.99 0.88 0.99 0.98 
 
Conclusions: 3D γ parameters of the in vivo dose distributions are 
highly correlated with DVH and EUD parameters. The lack of 
correlation with the D99 is logical since underdosages are hardly ever 
observed in the PTV of in vivo dose distributions for H&N VMAT 
treatments.  
These results indicate that γ criteria from in vivo dose evaluation that 
have a clinical relevance in terms of DVH and EUD parameters can 
readily be obtained. This pilot study paves the way for moving from 
hard-to-interpret γ-analysis results to the clinically more common and 
relevant DVH and EUD parameters. This will provide radiation 
oncologists with more insight in the clinical relevance of observed 
deviations during in vivo dosimetry. 
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Purpose/Objective: Pre-treatment quality assurance of radiotherapy 
plans is an essential check of the treatment planning system (TPS) 
dose calculation, as well as the plan transfer to the linear 
accelerator. With increasing numbers of complex treatments – 
including volumetric modulated arc therapy (VMAT) – the burden of 
individual linac-based QA has implications for workflow. In this work 
we introduce an automated Monte Carlo verification system for VMAT 
treatments, with the aim of reducing or replacing linac 
measurements. The system allows dose statistics to be reported for 
individual ROIs, and is able to accept plans exported from a record-
and-verify system, allowing a two-way check of plan transfer. 
Materials and Methods: The verification system is triggered when 
DICOM-RT format files (plan, CT, structures and dose) are exported 
from a TPS. The system automatically prepares and reformats the files 
into instructions for Monte Carlo simulation using GATE/GEANT4. 
Calculations on the patient’s CT dataset are then scheduled on a 44 
CPU cluster. The outputs are automatically merged and gamma 
analysis performed against the planned dose distribution.  
In order to validate the Monte Carlo model, comparisons were made 
to water tank measurements for depth-dose curves, profiles and 
output factors. Further validation was performed by delivering 5 
prostate and 5 head and neck VMAT plans to a cylindrical phantom 
(Delta4), and comparing the results to Monte Carlo simulations of the 
same geometry. To demonstrate the potential of the system for 
routine use, a prostate and head and neck VMAT patient were verified 
and their results interpreted. 
 
 
Results: The model showed good agreement against water tank 
measurements, with >95% of points passing a 2%/2mm gamma analysis 
for depth-dose curves at a range of field sizes. Validation of the VMAT 
simulation against the Delta4 gave results consistent with our 
accepted tolerance for pre-treatment QA, with pass rates of 98.6 (± 
0.9) % for the prostates and 95.8 (± 2.6) % for the head and necks at 
the 3%/3mm gamma level. 
Full dosimetric verification on a patients CT data took the system 10-
12 hours on the present computing cluster, in order to achieve < 2% 
uncertainty within the 5 % isodose volume. By setting up verification 
‘templates’ for individual sites, it was possible to report the gamma 
passes for various relevant ROIs within prostate and head and neck 
plans.  
Conclusions: An automated Monte Carlo verification system has been 
developed which allows for accurate, independent dose calculations 
on the patient CT dataset. ROI-specific results can be reported. 
Export is also allowed from a record-and-verify system to check plan 
transfer. This system demonstrates that highly complex plan QA can 
be performed using a software solution, allowing for the possibility of 
reducing or replacing machine-based measurements. Work is now 
being done to determine tolerances for the calculations, and 
expansion of the cluster is underway to meet clinical demands.  
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Purpose/Objective: In our institution, every clinical IMPT field must 
be verified before the delivery of the first fraction. Since 2007, when 
the new cyclotron was introduced into clinical practice, 2,528 IMPT 
fields have been verified. The purpose of this study was to analyze the 
results of all these fields and to decide whether patient specific 
verifications are necessary in the future. 
Materials and Methods: The treatment planning system automatically 
generates a steering file per field of each plan containing the 
information about selected Bragg peaks, their position and weights. 
Dosimetric verification of every steering file then consists of a 
measurement of two orthogonal profiles using an ionization chamber 
array consisting of two arms of thirteen ionization chambers each at a 
single depth in water. This is mounted on an automatically controlled 
water column such that measurements at different depths can be 
performed as required. The measured profiles are directly sent to the 
treatment planning system where they are compared with the 
predicted doses.  
Results: A summary of the results is shown in figure 1. The analysis of 
all verified IMPT fields have shown that more than 96% of verified 
fields were within our defined tolerances. There were no systematic 
errors in the position of the beam in relation to the isocenter or for 
the range in water. In addition, the precision (SD), calculated over all 
fields, is within ± 0.8 mm (SD) in all three directions. In the absolute 
dose, we have an accuracy of about 0.6 % of the predicted dose and 
precision of ±1.30 %. Although a small number of verifications were 
out of tolerance, most of these were due to problems with the 
measurement itself, e.g. chamber / water column calibration 
problems, malfunctioning ionisation chambers or bad cable 
connections. 
